FALSE
The statement is FALSE because there is no established TNM staging system for pheochromocytoma. According to the most authoritative guidelines, pheochromocytomas cannot be staged using traditional T-staging criteria like other solid tumors 1.
Why This Statement is Incorrect
No TNM Staging System Exists for Pheochromocytoma
The 2012 ESMO Clinical Practice Guidelines explicitly state: "There is no staging system for malignant pheochromocytoma" 1. This is fundamentally different from adrenocortical carcinoma (ACC), which does have a formal TNM classification system (the ENSAT system).
Malignancy is Defined by Metastases Only
For pheochromocytomas, the WHO classification defines malignancy exclusively by the presence of metastases to sites where chromaffin tissue is not normally present (e.g., liver, bone, lymph nodes) 1, 2. No histological finding, tumor size, or local invasion pattern can predict metastatic disease or define malignancy 1.
Size and Invasion Indicate Risk, Not Stage
While tumor size ≥5 cm and extra-adrenal location are associated with higher risk of malignancy 1, 2, these features do not translate into a T-staging system. A 6.0 cm confined pheochromocytoma would be considered high-risk for metastatic potential, but it cannot be classified as "pT2" because that designation does not exist for this tumor type.
Recent Staging Development (Important Caveat)
The 2022 WHO Classification mentions that a staging system for pheochromocytoma was introduced in the 8th Edition AJCC Cancer Staging Manual 3. However, this is a very recent development (post-2017), and the guidelines from 2012 that are most relevant to clinical practice clearly state no staging system existed at that time. The newer staging system has not been widely validated or incorporated into clinical practice guidelines yet.
Clinical Implications
- Risk stratification for pheochromocytomas uses tumor size (≥5 cm), extra-adrenal location, SDHB mutation status, and plasma methoxytyramine levels 1, 2
- Prognosis depends on tumor size, location, and genetic mutations rather than TNM stage 1
- All pheochromocytomas should be considered potentially malignant regardless of size or local characteristics 2
- The 5-year survival for malignant pheochromocytoma ranges from 34-60%, with significant heterogeneity 1
Bottom line: You cannot assign a pT2 designation to a pheochromocytoma because the traditional TNM staging framework does not apply to these tumors.